Spyre Therapeutics, Inc., headquartered in Waltham, Massachusetts, shared in a press release on September 3, 2026, that they will be participating in several investor conferences. The company, listed on the NASDAQ as SYRE, aims to advance immunology treatments by providing enhanced disease management, increased longevity, and easier treatment procedures for patients. No specific details of the conferences were provided.